Advertisement
Advertisement
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
15.04
USDSponsored
-0.31
-2.02%
Aug 07, 15:59 UTC -4
Closed
After-Market
15.07
+0.03
+0.20%
CTNM Earnings Reports
Positive Surprise Ratio
CTNM beat 4 of 10 last estimates.
40%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$3.84M
/-$0.42
Implied change from Q1 26 (Revenue/ EPS)
--
/-14.29%
Implied change from Q3 25 (Revenue/ EPS)
--
/-6.67%
Contineum Therapeutics, Inc. Class A Common Stock earnings per share and revenue
On May 05, 2026, CTNM reported earnings of -0.49 USD per share (EPS) for Q1 26, beating the estimate of -0.54 USD, resulting in a 9.61% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.82% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.42 USD, with revenue projected to reach 3.84 million USD, implying an decrease of -14.29% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Contineum Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Contineum Therapeutics, Inc. Class A Common Stock reported EPS of -$0.49, beating estimates by 9.61%, and revenue of $0.00, 0% as expectations.
How did the market react to Contineum Therapeutics, Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved up 3.82%, changed from $14.39 before the earnings release to $14.94 the day after.
When is Contineum Therapeutics, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Contineum Therapeutics, Inc. Class A Common Stock's next earnings report?
Based on 6
analysts, Contineum Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$0.42 and revenue of $3.84M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement